A common female health condition previously known as polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its complex nature, experts have announced. The change underscores that the condition affects multiple body systems—including the brain, ovaries, and metabolism—rather than being limited to the ovaries alone.

PCOS, now PMOS, affects an estimated four million women in the United Kingdom. The syndrome may present with symptoms such as abdominal pain, heavy menstrual bleeding, mood disturbances, weight gain, acne, excess body hair, and irregular or absent periods. The new terminology aims to move away from the misleading focus on the presence of ovarian cysts. While the original name highlighted cyst-like structures on the ovaries, these are in fact immature follicles that have not progressed to ovulation, rather than true cysts. Not all women with the condition display these follicles, but diagnosis can still be made with at least two symptoms including irregular menstruation, excess body hair, or acne.

Experts say the condition stems from abnormal hormonal signaling in the brain, where irregular secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) interferes with ovulation and hormone balance. This hormonal disruption often leads to insulin resistance, a key feature of PMOS that contributes to challenges with weight control and elevates the risk of type 2 diabetes and cardiovascular disease.

Victoria Hindle, a 43-year-old from Manchester, spent nearly a decade seeking a diagnosis for her abdominal pain, heavy periods, low mood, and weight issues. After receiving the new PMOS diagnosis earlier this year, she finally accessed appropriate treatment. Hindle, who was previously misdiagnosed with irritable bowel syndrome and repeatedly told to lose weight without explanation, credits the name change with helping her understand her condition and manage her health more effectively. She was later diagnosed with type 2 diabetes and began treatment with the medication tirzepatide, which has improved her blood sugar control, reduced her weight by seven stones, and restored her menstrual cycle.

Another patient, Michelle Akpata, a 30-year-old radio presenter from North London, was diagnosed with PCOS in 2021 after significant weight gain, excess hair growth, and fatigue, despite lacking ovarian cysts. She reports that her initial treatment advice was limited to painkillers, lifestyle modification, and private cosmetic procedures, with little attention given to the metabolic aspects of the syndrome. After undergoing weight-loss surgery and starting tirzepatide, Akpata reported significant improvements in her symptoms and quality of life.

Medical professionals involved in the renaming emphasize that PMOS requires broader clinical awareness, highlighting the importance of assessing metabolic indicators such as blood sugar, cholesterol, and blood pressure in affected women. Treatment strategies often include lifestyle and dietary changes, and medications like metformin to improve insulin sensitivity.

Cardiff University endocrinology professor Aled Rees, who led the name-change initiative, notes that despite the updated terminology, increased education for healthcare providers and public awareness are needed for meaningful improvements in care. Similarly, University College London’s Dr. Vikram Talaulikar cautions that while the name change brings new attention to PMOS, shifts in clinical practice may take time. He encourages women who suspect they may have the condition to discuss PMOS with their healthcare providers.

The reclassification of this condition marks a significant step in recognizing its systemic impact, moving beyond a narrow ovarian-focused understanding, and may lead to better diagnosis, treatment, and long-term management for millions of women.